FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 15:13:44 2024-06-21 EDT | ||
| 7.01 EUR | -0.99% |
|
| Current month | -19.61% | ||
| 1 month | -20.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 7.01 | -0.99% |
| 24-06-20 | 7.08 | -1.67% |
| 24-06-19 | 7.2 | -1.50% |
| 24-06-18 | 7.31 | +0.69% |
| 24-06-17 | 7.26 | +5.68% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 03:13 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG01QC |
| ISIN | DE000MG01QC7 |
| Date issued | 2024-03-11 |
| Strike | 1,325 kr |
| Maturity | Unlimited |
| Parity | 6.4 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.78 € |
|---|---|
| Lowest since issue | 6.87 € |
| Spread | 0.02 € |
| Spread % | 0.28% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- Certificat
